Secretory leukocyte protease inhibitor reverses inhibition by CNS myelin, promotes regeneration in the optic nerve, and suppresses expression of the transforming growth factor-β signaling protein Smad2. Academic Article uri icon

Overview

abstract

  • After CNS injury, axonal regeneration is limited by myelin-associated inhibitors; however, this can be overcome through elevation of intracellular cyclic AMP (cAMP), as occurs with conditioning lesions of the sciatic nerve. This study reports that expression of secretory leukocyte protease inhibitor (SLPI) is strongly upregulated in response to elevation of cAMP. We also show that SLPI can overcome inhibition by CNS myelin and significantly enhance regeneration of transected retinal ganglion cell axons in rats. Furthermore, regeneration of dorsal column axons does not occur after a conditioning lesion in SLPI null mutant mice, indicating that expression of SLPI is required for the conditioning lesion effect. Mechanistically, we demonstrate that SLPI localizes to the nuclei of neurons, binds to the Smad2 promoter, and reduces levels of Smad2 protein. Adenoviral overexpression of Smad2 also blocked SLPI-induced axonal regeneration. SLPI and Smad2 may therefore represent new targets for therapeutic intervention in CNS injury.

publication date

  • March 20, 2013

Research

keywords

  • Myelin Sheath
  • Nerve Regeneration
  • Optic Nerve Injuries
  • Secretory Leukocyte Peptidase Inhibitor
  • Smad2 Protein

Identity

PubMed Central ID

  • PMC3684282

Scopus Document Identifier

  • 84877096210

Digital Object Identifier (DOI)

  • 10.1523/JNEUROSCI.5321-12.2013

PubMed ID

  • 23516280

Additional Document Info

volume

  • 33

issue

  • 12